MedPath

Miller, Brian

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (100.0%)

Tocilizumab in Schizophrenia

Phase 1
Recruiting
Conditions
Psychotic Disorders
Schizophrenia
Interventions
Drug: Normal saline
First Posted Date
2016-08-22
Last Posted Date
2023-07-21
Lead Sponsor
Brian Miller
Target Recruit Count
20
Registration Number
NCT02874573
Locations
🇺🇸

Augusta University, Augusta, Georgia, United States

Siltuximab in Schizophrenia

Phase 1
Recruiting
Conditions
Schizophrenia
Psychotic Disorders
Interventions
Drug: normal saline
First Posted Date
2016-06-13
Last Posted Date
2023-07-21
Lead Sponsor
Brian Miller
Target Recruit Count
30
Registration Number
NCT02796859
Locations
🇺🇸

Augusta University, Augusta, Georgia, United States

An Open-Label Trial of Tocilizumab in Schizophrenia

Phase 1
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2012-10-02
Last Posted Date
2021-07-29
Lead Sponsor
Brian Miller
Target Recruit Count
8
Registration Number
NCT01696929
Locations
🇺🇸

Georgia Health Sciences University, Augusta, Georgia, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.